Citations

Showing 10 of 108048 citations.

Remimazolam Sedation and Neuraxial Anesthesia in a Patient with Amyotrophic Lateral Sclerosis Undergoing an Open Colectomy: A Case Report
Nimma, Sindhuja, Gans, Asaf , Wardhan, Richa, Allen, Wesley L. , Allen, Wesley

Mayo Clinic

A&A Practice | December 18, 2023 | Volume: 17 | Issue: 12 | Pages: e01733

10.1213/xaa.0000000000001733 | PMID 38109186 Get It

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease involving the upper and lower motor neurons. Perioperative management of patients with ALS can be challenging due to the risk of hemodynamic instability, aspiration, and ventilatory failure. We discuss a 58-year-old male patient with ALS who underwent open abdominal surgery under regional anesthesia utilizing a remimazolam infusion for sedation. While various sedation agents have been used successfully in patients with ALS, remimazolam, a new short-acting benzodiazepine with unique pharmacologic properties and reversible anxiolysis, provides amnesia while avoiding ventilatory depression.
Surgically Resected Cardiac Angiosarcoma: Survival Analysis from the National Cancer Database
Rahouma, Mohamed , Baudo, Massimo , Khairallah, Sherif , Lau, Christopher , Gaudino, Mario , Ahmed, Magdy M. El‐Sayed , Kumar, Akshay , Lorusso, Roberto , Mick, Stephanie L., El-Sayed Ahmed, Magdy M , Gaudino, Mario , Lorusso, Roberto , Kumar, Akshay , Rahouma, Mohammed

Mayo Clinic

Journal of Clinical Medicine | December 18, 2023 | Volume: 12 | Issue: 24 | Pages: 7764

10.3390/jcm12247764 | PMID 38137833 Get It

Angiosarcoma is a rare type of soft-tissue sarcoma arising from endothelial cells. It is considered ‘high-grade’ by definition, reflecting its aggressive behavior. We sought to investigate the role of surgery in cardiac angiosarcoma, identify late mortality predictors, and identify interactions with other modalities in its treatment using a national dataset. The 2004–2017 National Cancer Database was reviewed for patients with primary cardiac angiosarcoma. Late mortality predictors were evaluated with Kaplan–Meier curves and Cox regression analysis. Surgery in primary cardiac angiosarcoma was performed in 130 patients (median age 50.5 years; female sex 36.9%). The median follow up was 72.02 months, with a median overall survival (OS) of 14.32 months. In patients treated with surgery in combination with other modalities compared with those treated with surgery alone, median OSs were 17.28 and 2.88 months, respectively (log-rank = 0.018). Older patients (age > 57 years) experienced lower OS compared to those with an age < 57 (log-rank = 0.012). This may be partially explained by the difference in treatment strategies among age groups: those with increasing age, less surgery (p = 0.037), and less chemotherapy (p < 0.001) were chosen. With multivariable Cox regression analysis, age and race other than white or black were identified to be significant independent predictors of late mortality. Cardiac angiosarcoma has poor overall survival, and our findings should further encourage the use of surgery in combination with other therapeutic modalities in treating such an aggressive disease whenever possible.
Age-associated changes in lineage composition of the enteric nervous system regulate gut health and disease
Kulkarni, Subhash , Saha, Monalee , Slosberg, Jared , Singh, Alpana , Nagaraj, Sushma , Becker, Laren , Zhang, Chengxiu , Bukowski, Alicia, Wang, Zhuolun, Liu, Guosheng , Leser, Jenna , Bakhshi, Shriya, Vincent, Elizabeth , Pasricha, Pankaj J. , Singh, Alpana , Nagaraj, Sushma , Kulkarni, Subhash , Kumar, Mithra R. , Anderson, Matthew J , Lewandoski, Mark , Goff, Loyal A.

Mayo Clinic

eLife | December 18, 2023 | Volume: 12 | Issue: No issue available | Pages: No page available

10.7554/elife.88051.2 Get It

The enteric nervous system (ENS), a collection of neural cells contained in the wall of the gut, is of fundamental importance to gastrointestinal and systemic health. According to the prevailing paradigm, the ENS arises from progenitor cells migrating from the neural crest and remains largely unchanged thereafter. Here, we show that the lineage composition of maturing ENS changes with time, with a decline in the canonical lineage of neural-crest derived neurons and their replacement by a newly identified lineage of mesoderm-derived neurons. Single cell transcriptomics and immunochemical approaches establish a distinct expression profile of mesoderm-derived neurons. The dynamic balance between the proportions of neurons from these two different lineages in the post-natal gut is dependent on the availability of their respective trophic signals, GDNF-RET and HGF-MET. With increasing age, the mesoderm-derived neurons become the dominant form of neurons in the ENS, a change associated with significant functional effects on intestinal motility which can be reversed by GDNF supplementation. Transcriptomic analyses of human gut tissues show reduced GDNF-RET signaling in patients with intestinal dysmotility which is associated with reduction in neural crest-derived neuronal markers and concomitant increase in transcriptional patterns specific to mesoderm-derived neurons. Normal intestinal function in the adult gastrointestinal tract therefore appears to require an optimal balance between these two distinct lineages within the ENS.
Radiomics for Differentiation of Pediatric Posterior Fossa Tumors: A Meta-Analysis and Systematic Review of the Literature
Garaba, Alexandru , Ponzio, Francesco , Grasso, E , Brinjikji, Waleed , Fontanella, Marco Maria , Maria, Lucio De , De Maria, Lucio , Fontanella, Marco Maria

Mayo Clinic

Cancers | December 18, 2023 | Volume: 15 | Issue: 24 | Pages: 5891

10.3390/cancers15245891 | PMID 38136435 Get It

Purpose: To better define the overall performance of the current radiomics-based models for the discrimination of pediatric posterior fossa tumors. Methods: A comprehensive literature search of the databases PubMed, Ovid MEDLINE, Ovid EMBASE, Web of Science, and Scopus was designed and conducted by an experienced librarian. We estimated overall sensitivity (SEN) and specificity (SPE). Event rates were pooled across studies using a random-effects meta-analysis, and the χ2 test was performed to assess the heterogeneity. Results: Overall SEN and SPE for differentiation between MB, PA, and EP were found to be promising, with SEN values of 93% (95% CI = 0.88–0.96), 83% (95% CI = 0.66–0.93), and 85% (95% CI = 0.71–0.93), and corresponding SPE values of 87% (95% CI = 0.82–0.90), 95% (95% CI = 0.90–0.98) and 90% (95% CI = 0.84–0.94), respectively. For MB, there is a better trend for LR classifiers, while textural features are the most used and the best performing (ACC 96%). As for PA and EP, a synergistic employment of LR and NN classifiers, accompanied by geometrical or morphological features, demonstrated superior performance (ACC 94% and 96%, respectively). Conclusions: The diagnostic performance is high, making radiomics a helpful method to discriminate these tumor types. In the forthcoming years, we expect even more precise models.
All that hemolyzes with complement is not cold agglutinin syndrome
Jacobs, Jeremy W. , Adkins, Brian D. , Jacobs, Jeremy W , Booth, Garrett , Adkins, Brian David , Booth, Garrett S.

Mayo Clinic

Revista Paulista de Pediatria | December 18, 2023 | Volume: 42 | Issue: No issue available | Pages: No page available

10.1590/1984-0462/2024/42/2023144 | PMID 38126441 Get It

A pooled patient‐reported outcomes analysis of moderately hypofractionated proton beam therapy and photon‐based intensity modulated radiation therapy for low‐ or intermediate‐risk prostate cancer
Lukez, Alexander , Stish, Bradley J. , Hallman, M.A. , Horwitz, Eric M. , Vapiwala, Neha , Wong, J.K. , Davis, Brian J. , Wong, Jessica Karen , Handorf, Elizabeth A. , Mendenhall, Nancy P. , Henderson, Randal H.

Mayo Clinic

The Prostate | December 18, 2023 | Volume: 84 | Issue: 4 | Pages: 395-402

10.1002/pros.24660 | PMID 38108113 Get It

AbstractBackgroundWe sought to characterize and compare late patient‐reported outcomes (PROs) after moderately hypofractionated intensity modulated radiation therapy (IMRT) and proton beam therapy (PBT) for localized prostate cancer (PC).MethodsThis multi‐institutional analysis included low‐ or intermediate‐risk group PC patients treated with moderately hypofractionated radiation to an intact prostate stratified by treatment modality: IMRT or PBT. The primary outcomes were prospectively collected patient‐reported late gastrointestinal (GI) and genitourinary (GU) toxicity assessed by International Prostate Symptom Score (IPSS) and Expanded PC Index Composite (EPIC). Multivariable regression analysis (MVA) controlling for age, race, and risk group tested the effect of time, treatment, and their interaction.Results287 IMRT and 485 PBT patients were included. Intermediate risk group (81.2 vs. 68.2%; p < 0.001) and median age at diagnosis (70 vs. 67 years; p < 0.001) were higher in the IMRT group. On MVA, there was no significant difference between modalities. PBT IPSS did not differ from IMRT IPSS at 12 months (odds ratio [OR], 1.19; p = 0.08) or 24 months (OR, 0.99; p = 0.94). PBT EPIC overall GI function at 12 months (OR, 3.68; p = 0.085) and 24 months (OR 2.78; p = 0.26) did not differ from IMRT EPIC overall GI function. At 24 months, urinary frequency was no different between PBT and IMRT groups (OR 0.35; p = 0.096).ConclusionsThis multi‐institutional analysis of low‐ or intermediate‐risk PC treated with moderately hypofractionated PBT and IMRT demonstrated low rates of late patient‐reported GI and GU toxicities. After covariate adjustment, late GI and GU PROs were not significantly different between PBT or IMRT cohorts.
The Effects of Protein and Carbohydrate Supplementation, with and without Creatine, on Occupational Performance in Firefighters
Elstad, Kaia, Malone, Conley, Luedke, Joel, Jaime, Salvador J., Dobbs, Ward C. , Kerksick, Chad M. , Markert, Adam, Jagim, Andrew R. , Kerksick, Chad M , Jagim, Andrew R , Almonroeder, Thomas Gus

Mayo Clinic

Nutrients | December 18, 2023 | Volume: 15 | Issue: 24 | Pages: 5134

10.3390/nu15245134 | PMID 38140393 Get It

Background: The purpose of this study was to assess the effects of protein and carbohydrate supplementation, with and without creatine, on occupational performance in firefighters. Methods: Using a randomized, double-blind approach, thirty male firefighters (age: 34.4 ± 8.4 yrs., height: 1.82 ± 0.07 m; weight: 88.6 ± 12.5 kg; BF%: 17.2 ± 5.8%) were randomized to receive either (A.) 25 g of whey protein isolate + 25 g of carbohydrate powder (ProCarb group); or (B.) ProCarb + 5 g of creatine (Creatine group) in a double-blind fashion over a period of 21–26 days (depending on shift rotations) to evaluate the impact of supplementation on occupation-specific performance. At baseline and following supplementation, firefighters completed a battery of tests. These tests included an aerobic speed test on an air-braked cycle ergometer followed by the hose carry, body drag, stair climb, and Keiser sled hammer for time. Results: No significant differences in measures of performance were observed at baseline (p > 0.05). There was a significant main effect for time observed for rescue, stair climb, total time to completion, and time trial performance (p < 0.05). There was a significant group × time (p < 0.05) interaction for rescue and forcible entry. Independent sample t-tests indicated that the Creatine group experienced a greater reduction (from baseline) in completion time for the rescue (1.78 ± 0.57 s, 95% CI: 0.61, 2.95 s, p = 0.004) and forcible entry (2.66 ± 0.97 s, 95% CI: 0.68, 4.65 s, p = 0.01) tests compared to the ProCarb group. No significant group × time interactions were observed for the hose line advance, stair climb, total time to completion, and time trial performance (p > 0.05). Conclusions: The addition of supplemental creatine to a protein and carbohydrate supplement to the diet of career firefighters throughout a three week period improves occupational performance in firefighters in specific areas of high-intensity, repetitive actions.
Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
Rencsok, Emily M. , Slopen, Natalie , McManus, Hannah D. , Autio, Karen A. , Morgans, Alicia K. , McSwain, Lawrence, Barata, Pedro C. , Cheng, Heather H. , Dreicer, Robert , Gerke, Travis , Green, Rebecca , Heath, Elisabeth I. , McKay, Rana R. , Nowak, Joel , Pileggi, Shannon , Pomerantz, Mark M., Whang, Young E. , Ragin, Camille , Vinson, Jake , Villanti, Paul , Haneuse, Sebastien , Mucci, Lorelei A. , George, Daniel J. , Registry, for the IRONMAN, Barata, Pedro , Howard, Lauren E , McKay, Rana R , Nowak, Joel , Pileggi, Shannon , Pomerantz, Mark M , Rathkopf, Dana E , Tagawa, Scott T , Whang, Young E , Ragin, Camille , Odedina, Folakemi , Kantoff, Philip W , Vinson, Jake , Villanti, Paul , Haneuse, Sebastien , Mucci, Lorelei A , George, Daniel J , Cheng, Heather H , Morgans, Alicia K , Dreicer, Robert , Howard, Lauren E. , Tagawa, Scott T. , Kantoff, Philip W. , Registry, for the IRONMAN

Mayo Clinic

Cancer Research Communications | December 18, 2023 | Volume: 4 | Issue: 1 | Pages: 55-64

10.1158/2767-9764.crc-23-0446 | PMID 38108490 Get It

Abstract Bone pain is a well-known quality-of-life detriment for individuals with prostate cancer and is associated with survival. This study expands previous work into racial differences in multiple patient-reported dimensions of pain and the association between baseline and longitudinal pain and mortality. This is a prospective cohort study of individuals with newly diagnosed advanced prostate cancer enrolled in the International Registry for Men with Advanced Prostate Cancer (IRONMAN) from 2017 to 2023 at U.S. sites. Differences in four pain scores at study enrollment by race were investigated. Cox proportional hazards models and joint longitudinal survival models were fit for each of the scale scores to estimate HRs and 95% confidence intervals (CI) for the association with all-cause mortality. The cohort included 879 individuals (20% self-identifying as Black) enrolled at 38 U.S. sites. Black participants had worse pain at baseline compared with White participants, most notably a higher average pain rating (mean 3.1 vs. 2.2 on a 10-point scale). For each pain scale, higher pain was associated with higher mortality after adjusting for measures of disease burden, particularly for severe bone pain compared with no pain (HR, 2.47; 95% CI: 1.44–4.22). The association between pain and all-cause mortality was stronger for participants with castration-resistant prostate cancer compared with those with metastatic hormone-sensitive prostate cancer and was similar among Black and White participants. Overall, Black participants reported worse pain than White participants, and more severe pain was associated with higher mortality independent of clinical covariates for all pain scales. Significance: Black participants with advanced prostate cancer reported worse pain than White participants, and more pain was associated with worse survival. More holistic clinical assessments of pain in this population are needed to determine the factors upon which to intervene to improve quality of life and survivorship, particularly for Black individuals.
Limitations in Evaluating Machine Learning Models for Imbalanced Binary Outcome Classification in Spine Surgery: A Systematic Review
Ghanem, Marc , Ghaith, Abdul Karim , El-Hajj, Victor Gabriel , Bhandarkar, Archis R. , Giorgio, Andrea de , Elmi‐Terander, Adrian , Bydon, Mohamad , Bhandarkar, Archis, de Giorgio, Andrea , Ghaith, Abdul Karim , Elmi-Terander, Adrian , El-Hajj, Victor Gabriel

Mayo Clinic

Brain Sciences | December 18, 2023 | Volume: 13 | Issue: 12 | Pages: 1723

10.3390/brainsci13121723 | PMID 38137171 Get It

Clinical prediction models for spine surgery applications are on the rise, with an increasing reliance on machine learning (ML) and deep learning (DL). Many of the predicted outcomes are uncommon; therefore, to ensure the models’ effectiveness in clinical practice it is crucial to properly evaluate them. This systematic review aims to identify and evaluate current research-based ML and DL models applied for spine surgery, specifically those predicting binary outcomes with a focus on their evaluation metrics. Overall, 60 papers were included, and the findings were reported according to the PRISMA guidelines. A total of 13 papers focused on lengths of stay (LOS), 12 on readmissions, 12 on non-home discharge, 6 on mortality, and 5 on reoperations. The target outcomes exhibited data imbalances ranging from 0.44% to 42.4%. A total of 59 papers reported the model’s area under the receiver operating characteristic (AUROC), 28 mentioned accuracies, 33 provided sensitivity, 29 discussed specificity, 28 addressed positive predictive value (PPV), 24 included the negative predictive value (NPV), 25 indicated the Brier score with 10 providing a null model Brier, and 8 detailed the F1 score. Additionally, data visualization varied among the included papers. This review discusses the use of appropriate evaluation schemes in ML and identifies several common errors and potential bias sources in the literature. Embracing these recommendations as the field advances may facilitate the integration of reliable and effective ML models in clinical settings.
Determinants of outcomes and advances in CD19‐directed chimeric antigen receptor therapy for B‐cell acute lymphoblastic leukemia
Gupta, Supriya , Kohorst, Mira A. , Kohorst, Mira , Alkhateeb, Hassan B , Alkhateeb, Hassan B.

Mayo Clinic

European Journal of Haematology | December 18, 2023 | Volume: 112 | Issue: 1 | Pages: 51-63

10.1111/ejh.14132 | PMID 38105391 Get It

AbstractRelapsed and refractory B‐cell acute lymphoblastic leukemia (B‐ALL) is an aggressive B‐cell neoplasm associated with poor outcomes. Conventional multiagent chemotherapy and bispecific antibody therapy may induce remission; however, relapse rates remain high and overall survival is poor. Chimeric antigen receptor T‐cell (CAR‐T) therapy provides durable, deep complete remission, and long‐term cures in relapsed and refractory B‐ALL. However, with this new treatment modality, 10%–30% of patients do not achieve remission, and over 50% experience relapse after therapy. Currently, there are two approved CD19‐specific CAR‐T cell constructs in B‐ALL, Tisagenlecleucel and Brexucabtagene Autoleucel by the United States Food and Drug Administration, and the European Medicines Agency (EMA). In this review, we discuss patients, disease, and CAR‐T predictors of outcomes in B‐ALL. We describe the two approved CD19‐directed CAR‐T cell products, review the current literature, and discuss factors associated with high risks of therapy failure and future direction in CAR‐T cell therapy for B‐ALL.